Difference between revisions of "Anastrozole (Arimidex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Uterine" to "[[Category:Endometrial") |
||
| Line 31: | Line 31: | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| − | [[Category: | + | [[Category:Endometrial cancer medications]] |
[[Category:FDA approved in 1995]] | [[Category:FDA approved in 1995]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 19:15, 28 October 2018
General information
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Anastrozole (Arimidex) package insert PDF pages 10-11[1]
- Anastrozole (Arimidex) patient drug information (Chemocare)[4]
- Anastrozole (Arimidex) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/27/1995: Initial FDA approval
Also known as
- Brand names: Altraz, Anabrez, Anastraze, Anastrazol Rontag, Anastrol, Arimidex, Asiolex, Karomex, Leprofen, RUI SI YI, RUI Ting, Trozolet, Trozolite.